Perrigo (PRGO)
(Delayed Data from NYSE)
$24.37 USD
+0.12 (0.49%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $24.36 -0.01 (-0.04%) 6:18 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.37 USD
+0.12 (0.49%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $24.36 -0.01 (-0.04%) 6:18 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
Zacks News
What Makes Perrigo (PRGO) a New Buy Stock
by Zacks Equity Research
Perrigo (PRGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Perrigo (PRGO) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Perrigo (PRGO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -147.06% and 4.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 9.52% and 2.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Is SPDRSP PHARMA (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Perrigo (PRGO) Misses on Q3 Earnings, Lowers Earnings View
by Zacks Equity Research
Perrigo (PRGO) reports dismal third-quarter 2021 results. Stock declines.
Perrigo (PRGO) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -30.77% and -0.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Earnings Preview: Perrigo (PRGO) Q3 Earnings Expected to Decline
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo (PRGO) Stock Up on Irish Tax Bill Settlement Deal
by Zacks Equity Research
Perrigo (PRGO) agrees to pay an aggregate of approximately $345 million (Euro 297 million) to settle its tax liability notice from the Irish Office of the Revenue Commissioners issued in 2018.
Why Is Perrigo (PRGO) Up 7.1% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) to Acquire Another Self-Care Company HRA Pharma
by Zacks Equity Research
Perrigo (PRGO) offers to acquire HRA Pharma with several leading OTC brands in its portfolio for almost $2.1 billion. The acquisition will complete Perrigo's transformation into a leading self-care company.
Perrigo (PRGO) Q2 Earnings Lag, Sales Hurt by Weak Cold Season
by Zacks Equity Research
Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.
Perrigo (PRGO) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -18.03% and -3.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Perrigo (PRGO) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Perrigo (PRGO) reports dismal first-quarter 2021 results. The COVID-19 pandemic continues to hurt the company's top line.
Perrigo (PRGO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -10.71% and -0.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Earnings Preview: Perrigo (PRGO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.